Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder

Gagan Joshi, Eric Mick, Janet Wozniak, Daniel Geller, Jennifer Park, Samara Strauss, Joseph Biederman

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Objective: To compare antimanic response to olanzapine therapy in youth with bipolar disorder (BPD) based on the status of comorbidity with obsessive-compulsive disorder (OCD). Methods: Secondary analysis of identically designed 8-week open-label trials of olanzapine therapy in youth with BPD. Severity of mania assessed with the Young Mania Rating Scale (YMRS) and Clinical Global Impression (CGI) scales. Results: Of the 52 BPD subjects (mean age 8.4 ± 3.1 years) enrolled in the olanzapine trials (mean dose 8.5 ± 4.3 mg/day), 39% (n = 20) met criteria for comorbid OCD. Antimanic response in BPD subjects was significantly worse in the presence of comorbid OCD (YMRS mean reduction: -5.9 ± 13.1 versus -13.7 ± 18.8, p = 0.04; ≥ 30% reduction: 25% versus 63%, p = 0.008; CGI-Improvement score ≤ 2: 25% versus 68%, p = 0.003). There was no difference in the rate of dropouts (50% versus 29%, p = 0.2) or adverse effects in BPD subjects with or without comorbid OCD. Conclusions: Less than expected antimanic response to olanzapine therapy in the presence of comorbidity with OCD suggests that OCD is an important functionally impairing psychiatric comorbidity that may impact the efficacy of antimanic agents in youth with BPD. This study is limited by its design of secondary analysis of data from trials of an uncontrolled nature. Further prospective controlled trials are warranted.

Original languageEnglish
Pages (from-to)196-204
Number of pages9
JournalBipolar Disorders
Volume12
Issue number2
DOIs
StatePublished - Mar 2010
Externally publishedYes

Keywords

  • Bipolar disorder
  • OCD
  • Olanzapine
  • Youth

Fingerprint

Dive into the research topics of 'Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder'. Together they form a unique fingerprint.

Cite this